Key Highlights
AOTI, Inc. is firmly in focus on 1 September 2026 after LSE:AOTI fell 12.42%, making the medical-technology company one of the notable decliners in the current market session.
The decline comes despite a series of important operational developments that have substantially strengthened the company's Long-term Growth story.
AOTI has reported 10% first-half 2026 Revenue growth to approximately $35 million, while underlying revenue growth excluding the Arizona Medicaid impact reached approximately 18%.
The company also reported strong growth from its Veterans Administration business, with revenue increasing approximately 15% year over year.
The most important development for the Investment case, however, is the proposed expansion of Medicare coverage for topical oxygen therapy.
A proposed Local Coverage Determination would establish coverage criteria for topical oxygen therapy for Medicare beneficiaries with diabetic foot ulcers that have failed to heal following four consecutive weeks of optimised care.
The proposal could dramatically expand AOTI's addressable US market for its TWO2 Topical Wound Oxygen therapy.
AOTI already has a strong position in the topical oxygen market, and broader Medicare coverage could substantially increase the number of eligible patients and healthcare providers able to access the therapy.
The latest public meeting relating to the proposed coverage determination was also highly encouraging, with stakeholder comments reported as unanimously supportive.
Yet today's share-price decline shows that investors are not simply focusing on the operational opportunity.
AOTI's shares had already risen dramatically during 2026, reaching a 52-week high of approximately 150p on 26 August.
Today's decline therefore appears to reflect a combination of profit-taking, valuation concerns, exceptionally strong previous gains and investors reassessing the timing of the Medicare opportunity.
Why Is AOTI LSE:AOTI in Focus Today?
AOTI is attracting attention because the company sits at the intersection of healthcare, medical technology and the growing Demand for cost-effective treatment of chronic wounds.
Its principal TWO2 therapy is designed to help heal difficult chronic wounds using intermittent topical oxygen.
The target patient population is particularly important.
Chronic wounds, including diabetic foot ulcers, can be difficult and expensive to treat.
Patients who Fail to heal through standard care can face repeated medical interventions, extended treatment periods and, in severe cases, amputation.
A therapy that can improve healing outcomes could therefore potentially generate significant clinical and economic benefits.
This is where the Medicare coverage development becomes so important.
A broader reimbursement framework could remove one of the biggest barriers facing adoption of innovative medical technologies: whether healthcare providers can obtain payment for the treatment.
If Medicare coverage becomes final, AOTI could gain access to a much larger patient population in the United States.
That is the central reason investors continue to watch LSE:AOTI despite today's sharp decline.
Why Did LSE:AOTI Fall 12.42% on 1 September 2026?
The 12.42% decline in LSE:AOTI on 1 September 2026 is particularly notable because the company's recent operational news has been largely positive.
The share price had climbed to approximately 150p on 26 August, representing a substantial increase from earlier 2026 levels.
A rapid rally of this magnitude can create conditions for profit-taking.
Short-term traders who accumulated shares earlier in the year may choose to lock in gains after the stock reaches a new high.
That can produce sharp reversals even when the underlying Business outlook has not materially deteriorated.
There is also a valuation consideration.
AOTI's shares have been rerated significantly as investors have begun pricing in the potential impact of expanded Medicare coverage.
The proposed coverage determination is not yet equivalent to a final nationwide reimbursement outcome.
Therefore, investors must distinguish between the potential future market opportunity and revenue that has already been realised.
Today's decline may consequently represent a reassessment of expectations rather than a deterioration in AOTI's core operations.
Medicare Coverage Is the Biggest Potential Catalyst
The proposed Medicare coverage determination is arguably the most important development in AOTI's history.
The proposal would establish reasonable and necessary coverage criteria for topical oxygen therapy for Medicare beneficiaries with diabetic foot ulcers that have failed to heal after four consecutive weeks of optimised care.
This could materially expand AOTI's US addressable market.
The US Medicare population includes approximately 69 million beneficiaries, creating a potentially enormous pool of patients.
However, the relevant population is considerably smaller than the total Medicare population because coverage would apply only to patients meeting the specified clinical criteria.
Nevertheless, the opportunity could still be substantial.
The biggest advantage is that reimbursement coverage could make it easier for physicians and healthcare providers to prescribe TWO2 for eligible patients.
Without reimbursement, even clinically effective therapies can struggle to achieve broad adoption.
With coverage, the commercial equation changes considerably.
The Latest Public Meeting Was Encouraging
The most recent development occurred on 27 August 2026, when the public meeting connected with the proposed topical oxygen therapy coverage determination concluded.
The meeting formed part of the public comment process before the proposed determination moves toward finalisation.
The comments were reported as unanimously favourable toward the proposed coverage language.
That is an encouraging signal because it suggests strong stakeholder support for establishing Medicare coverage.
However, investors should remain aware that a proposed determination and a final determination are not the same thing.
The final wording, implementation requirements, effective date and coverage criteria will ultimately determine the commercial impact.
Therefore, the next regulatory announcement could become one of the most important catalysts for LSE:AOTI.
TWO2 Is the Core Product Behind the Story
AOTI's TWO2 therapy is the central product driving the investment thesis.
It provides intermittent topical oxygen therapy for chronic wounds.
The company differentiates TWO2 from continuous topical oxygen systems by using intermittent oxygen delivery.
AOTI has built a substantial body of clinical evidence around the therapy, including real-world evidence and peer-reviewed studies.
One recent real-world analysis involving more than 2,000 patients reported a high rate of complete durable wound healing despite the wounds having already failed to heal through previous treatment.
These data are important because healthcare reimbursement decisions increasingly depend on evidence demonstrating both clinical effectiveness and potential economic benefits.
The company's objective is not simply to show that TWO2 can heal wounds.
It is also to demonstrate that better healing outcomes can reduce the long-term costs associated with chronic wound management.
First-Half Revenue Growth Remains Strong
The underlying business is already growing.
AOTI reported first-half 2026 revenue of approximately $35 million, representing 10% growth compared with approximately $31.8 million during the first half of 2025.
Underlying revenue growth was approximately 18% when excluding Arizona Medicaid.
This distinction is important because AOTI stopped treating new Medicaid patients in Arizona from 1 April 2026.
The resulting disruption creates a temporary comparison effect.
Outside that specific issue, the company continued to demonstrate healthy demand.
The Veterans Administration business, which represented approximately 57% of revenue, delivered around 15% year-on-year growth.
That suggests the business is already benefiting from improving conditions in an important US healthcare channel.
Medicaid Remains an Important Growth Opportunity
Medicaid represented approximately 41% of AOTI's first-half revenue.
Underlying Medicaid revenue growth was approximately 21%, excluding Arizona.
Reported Medicaid growth was lower because of the Arizona change.
This demonstrates both the opportunity and risk associated with government healthcare programmes.
AOTI's growth is closely linked to reimbursement access.
When coverage is available and patients qualify, the company can potentially expand rapidly.
When coverage changes, growth can be interrupted.
That makes the Medicare coverage decision especially important.
A favourable final determination could provide a new growth engine comparable to or larger than the existing channels.
AOTI's Financial Position Has Improved
The company also entered the second half of 2026 with a relatively stronger Liquidity position.
Cash was approximately $13.8 million at 30 June 2026, compared with $13.4 million at the end of 2025.
Net Debt stood at approximately $6.3 million, compared with $6.5 million at the end of 2025.
This indicates that the company has maintained financial discipline while continuing to expand.
The improvement in Working Capital and strong Veterans Administration performance were important contributors.
For investors, this matters because AOTI does not appear to be relying solely on external funding to finance its expansion.
The ability to generate revenue and manage Cash Flow provides greater flexibility as the company prepares for a potential Medicare-driven increase in demand.
Why the Medicare Opportunity Could Be Transformational
The potential significance of Medicare coverage goes beyond simply adding another customer group.
It could alter the entire commercial landscape for TWO2.
Broader Medicare coverage could encourage healthcare providers to become more familiar with topical oxygen therapy.
Greater reimbursement visibility could also make it easier for AOTI to expand its sales infrastructure.
The company could potentially reach more wound-care specialists, podiatrists, vascular specialists and other healthcare professionals treating diabetic foot ulcers.
Successful Medicare adoption could also create a positive feedback loop.
More coverage could lead to more patients.
More patients could generate additional clinical evidence.
Additional evidence could encourage wider adoption.
Wider adoption could potentially support reimbursement expansion into other patient groups and insurance channels.
That is why investors are treating the proposed Medicare determination as such a significant event.
But Medicare Coverage Is Not Yet Guaranteed
The biggest caution is that investors are already anticipating a substantial portion of the potential opportunity.
A proposed coverage determination still has to progress through the remaining regulatory process.
The final determination could contain different wording or eligibility requirements.
There may also be practical implementation issues.
Healthcare providers need to understand the criteria.
Patients need to qualify.
Treatment must be appropriately documented.
Reimbursement procedures must operate efficiently.
Therefore, even if final coverage is approved, the commercial impact may develop progressively rather than immediately.
This distinction is essential when assessing today's share-price movement.
AOTI's Strong Share-Price Rally Raises the Stakes
AOTI's shares reached approximately 150p on 26 August 2026, marking a new 52-week high.
The dramatic increase in the share price means expectations have risen substantially.
That creates two competing forces.
On one side, the potential Medicare expansion could justify a much larger valuation if adoption accelerates.
On the other side, any regulatory delay, slower-than-expected uptake or disappointing commercial data could trigger further profit-taking.
This helps explain why LSE:AOTI can move by double-digit percentages even when there is no major negative operational announcement.
The market is now trading the stock partly on future expectations.
That naturally increases volatility.
Wasatch's Increased Stake Is Also Being Watched
Another notable development occurred in July when Wasatch Advisors increased its reported holding in AOTI to approximately 13.17%, up from 12.23%.
The increased ownership is relevant because it demonstrates continued institutional interest in the company's long-term potential.
Institutional buying does not guarantee future share-price performance, but it can reinforce confidence in the underlying business opportunity.
It also highlights that AOTI's story has moved beyond being followed solely as a small speculative medical-technology company.
The company is attracting attention from larger investment managers because of its potential exposure to the US chronic-wound market and Medicare reimbursement expansion.
What Investors Should Watch Next
The most important catalyst is the final Medicare coverage determination.
Investors should monitor whether the proposed criteria are adopted, modified or delayed.
The second Factor is the timing of implementation.
A favourable decision will be significantly more valuable if providers can begin using the therapy broadly without lengthy administrative delays.
The third is AOTI's underlying revenue growth.
The company needs to continue demonstrating organic growth while waiting for the Medicare opportunity.
The fourth is Veterans Administration performance.
The VA business remains a major contributor to revenue and has been delivering strong growth.
The fifth is Medicaid expansion outside Arizona.
The sixth is cash flow and net debt.
The company needs to maintain financial strength while investing in commercial infrastructure.
The Bull Case for LSE:AOTI
The bullish case is that AOTI is approaching a major reimbursement-driven growth inflection point.
The company already has a commercial product.
TWO2 has clinical evidence.
The business is generating substantial revenue.
First-half revenue grew 10%.
Underlying growth was approximately 18%.
VA revenue increased around 15%.
Cash remained around $13.8 million.
The proposed Medicare coverage could dramatically expand the addressable market.
The recent public meeting produced strong stakeholder support.
If final coverage is approved and adoption develops rapidly, AOTI could experience a substantial acceleration in revenue.
That could potentially support further Operating Leverage and stronger cash generation.
The Bear Case for LSE:AOTI
The bearish case is primarily about expectations and valuation.
The share price has already risen substantially.
The stock reached a new 52-week high just days before today's decline.
Investors may therefore have priced in significant Medicare success.
If final coverage is delayed or materially narrower than expected, the stock could experience further volatility.
There is also execution risk.
A favourable reimbursement decision does not guarantee that every eligible patient will receive TWO2.
Healthcare providers still need to adopt the therapy.
Sales infrastructure must scale.
Patient eligibility must be documented.
And AOTI must maintain clinical and economic evidence supporting adoption.
The company also remains exposed to changes in government healthcare policies.
Outlook for AOTI LSE:AOTI
The 12.42% fall in LSE:AOTI on 1 September 2026 does not change the central long-term investment story, but it does highlight how much expectation has now been built into the shares.
AOTI has strong operational momentum.
Revenue is growing.
The VA business is performing well.
Underlying Medicaid growth remains healthy outside Arizona.
Cash has remained relatively stable.
The company has a differentiated wound-care technology with clinical evidence.
Most importantly, the proposed Medicare coverage determination could significantly expand the US market opportunity.
That is the potential game changer.
However, investors should distinguish between potential market expansion and realised commercial revenue.
The final Medicare decision has not yet delivered the full economic benefit to AOTI.
The company's future growth will depend on how quickly eligible patients and healthcare providers adopt TWO2 once broader coverage becomes available.
For now, LSE:AOTI remains a high-growth, high-volatility healthcare stock where Medicare reimbursement, TWO2 adoption, underlying revenue growth, government healthcare programmes and valuation expectations are the key factors investors are watching most closely.
Today's decline may therefore be more about profit-taking and elevated expectations following the recent rally than a fundamental deterioration in the company's business.
The next major regulatory milestone could determine whether the recent pullback becomes a temporary consolidation or the beginning of a deeper reassessment of the shares.






Please wait processing your request...